Japan· JP-4291094F1020
ベルズチファン
A belzutifan product containing ベルズチファン, registered in Japan by ＭＳＤ, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Belzutifan is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX74 (belzutifan), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Belzutifan · ATC L01XX74
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of belzutifan costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Belzutifan · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- FR France$0.54
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ベルズチファン
- Manufacturer
- ＭＳＤ
- Country
- Japan (JP)
- ATC code
- L01XX74
- ATC class
- Belzutifan
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L01XX74
Belzutifan, as other registers publish it.
- PolandWeliregMerck Sharp & Dohme B.V.
- IcelandWeliregMerck Sharp & Dohme B.V.*
- DenmarkWELIREGMerck Sharp & Dohme B.V.
- United StatesWELIREGMerck Sharp & Dohme LLC
- CanadaWELIREGMERCK CANADA INC
- United StatesWELIREGMerck Sharp & Dohme LLC
- FinlandWELIREGMerck Sharp & Dohme B.V.
- CzechiaWELIREGMerck Sharp & Dohme B.V., Haarlem
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f8346ac8-a776-4709-b509-bb87e4e5abe2 GET /v1/drugs/f8346ac8-a776-4709-b509-bb87e4e5abe2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291094F1020",
"category": "内用薬",
"price_yen": 21916.8,
"generic_name": "ベルズチファン",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about belzutifan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.